1. Volume 62, Pages S68-S72 (December 2002)
Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union 
William C. Gerth, Giuseppi Remuzzi, Giancarlo Viberti, Thierry Hannedouche, Alberto Martinez-Castelao, Shahnaz Shahinfar, George W. Carides, Barry Brenner 
Kidney International 
Volume 62, Pages S68-S72 (December 2002)
DOI: /j s82.14.x
Copyright © 2002 International Society of Nephrology Terms and Conditions

2. Figure 1
Cumulative number of days with end-stage renal disease (ESRD) per patient by duration of follow-up. Symbols are: (dashed line) placebo; (solid line) losartan.
Kidney International  , S68-S72DOI: ( /j s82.14.x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

3. Figure 2
Estimated cumulative number of ESRD cases in the European Union (EU). Symbols are: (dashed line) placebo; (solid line) losartan.
Kidney International  , S68-S72DOI: ( /j s82.14.x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

4. Figure 3
Estimated cumulative ESRD-related costs in the EU. Symbols are: (dashed line) placebo; (solid line) losartan.
Kidney International  , S68-S72DOI: ( /j s82.14.x)
Copyright © 2002 International Society of Nephrology Terms and Conditions